Scott Zashin
Dallas, TXNPI 1255364048
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $53,100 of the $68,771 with a category attached, or 77.2%. 23 manufacturers reported payments, led by AbbVie at 44.9% of the total. Reporting peaked in 2019 at $24,157 and has fallen 97.7% since, to $551 in 2025.
Across 264 payments — averaging $260.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$31K
- Amgen$25K
- E.r. Squibb & Sons, L.L.C.$6K
- Novartis$4K
- Johnson & Johnson$396
- Genentech USA, Inc.$358
- plus $1K from 17 others
Across 5 payments — averaging $7412.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$32K
- E.r. Squibb & Sons, L.L.C.$5K
What the payments were for
- Consulting fees$3,5355%
- Speaking & faculty fees$53,10077%
- Travel & lodging$6,1839%
- Food & beverage$5,7078%
- Education$2460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 92 | $30,867 |
| Amgen(2 entities) | 58 | $25,354 |
| E.r. Squibb & Sons, L.L.C. | 13 | $6,167 |
| Novartis | 20 | $4,245 |
| Johnson & Johnson | 14 | $396 |
| Genentech USA, Inc. | 8 | $358 |
| AstraZeneca | 11 | $349 |
| Boehringer Ingelheim | 7 | $183 |
| UCB, Inc. | 7 | $180 |
| GSK | 8 | $156 |
| Lilly USA, LLC | 5 | $112 |
| Pfizer | 3 | $66 |
| Mallinckrodt Hospital Products Inc. | 3 | $62 |
| Medexus Pharma, Inc. | 3 | $57 |
| Sanofi | 2 | $42 |
| ANI Pharmaceuticals, Inc. | 2 | $40 |
| Fresenius Kabi USA, LLC | 2 | $32 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Organon | 1 | $19 |
| Sobi, Inc | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Octapharma USA, Inc. | 1 | $14 |
| Cumberland Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EnbrelEtanercept | 28 | $181,912 |
| Humira PenAdalimumab | 13 | $173,468 |
| Enbrel SureclickEtanercept | 20 | $145,620 |
| Enbrel MiniEtanercept | 18 | $138,706 |
| Cosentyx (2 Syringes)Secukinumab | 14 | $137,955 |
| OrenciaAbatacept/Maltose | 13 | $36,202 |
| BenlystaBelimumab | 18 | $29,856 |
| Cevimeline Hcl | 27 | $5,840 |
| Hydroxychloroquine Sulfate | 152 | $5,269 |
| MethotrexateMethotrexate Sodium | 88 | $2,514 |
| Leucovorin Calcium | 91 | $2,385 |
| Leflunomide | 30 | $1,907 |
| Prednisone | 172 | $1,573 |
| Butalb-Acetaminoph-Caff-CodeinButalbit/Acetamin/Caff/Codeine | 12 | $1,566 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 55 | $1,326 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenEnbrel | $25,354 | $181,91228 claims |
| NovartisCosentyx (2 Syringes) | $4,245 | $137,95514 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $6,167 | $36,20213 claims |
| GSKBenlysta | $156 | $29,85618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Texason file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.